Expression of SART3 tumor-rejection antigen in gastric cancers

Japanese Journal of Cancer Research

Volumn 91, Issue 3, 2000, Pages 337-342

  Niiya, Fumihiko ^a   Nishizaka, Shinya ^a   Matsunaga, Kazuko ^a   Koufuji, Kikuo ^a   Mori, Masaki ^b   Katai, Hitoshi ^c   Yamana, Hideaki ^a   Itoh, Kyogo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

A24; Cancer vaccine; Gastric cancer; HLA; SART3 antigen

Indexed keywords

HLA A ANTIGEN; PEPTIDE; TUMOR REJECTION ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER TISSUE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; PRIORITY JOURNAL; STOMACH CANCER;

EID: 0034074197     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2000.tb00950.x     Document Type: Article

References (15)

1. Van Der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van Den Eynde, B., Knuth, A. and Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254, 1643-1647 (1991).
2. Traversari, C., Van Der Bruggen, P., Lueseher, I. F., Lurquin, C., Chomez, P., Van Pel, A., De Plaen, E., Amar-Costesec, A. and Boon, T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med., 176, 1453-1457 (1992).
3. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E. and Rosenberg, S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med., 180, 347-352 (1994).
4. Gaugler, B., Van Den Eynde, B., Van Der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethe, B., Brasseur, F. and Boon, T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med., 179, 921-930 (1994).
5. Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E. and Rosenberg, S. A. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med., 183, 1185-1192 (1996).
6. Marchand, M., Van Baren, N., Weynants, W., Brichard, V., Dréno, B., Tessier, M. H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., Bourlond, A., Vanwijck, R., Liénard, D., Beauduin, M., Dietrich, P. Y., Russo, V., Kerger, J., Masucci, G., Jäger, E., De Greve, J., Atzpodien, J., Brasseur, F., Coulie, P. G., Van Der Bruggen, P. and Boon, T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer, 80, 219-230 (1999).
7. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H. and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4, 321-327 (1998).
8. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4, 328-332 (1998).
9. Boku, N., Ohtsu, A., Shimada, Y., Shirao, K., Seki, S., Saito, H., Sakata, U. and Hyodo, I. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol., 17, 319-323 (1999).
10. Wadler, S., Damle, S., Haynes, H., Kaleya, R., Schechner, R., Berkenblit, R., Ladner, R. D. and Murgo, A. Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract. J. Clin. Oncol., 17, 1771-1778 (1999).
11. Inoue, H., Mori, M., Honda, M., Li, J., Shibata, K., Mimori, K., Ueo, H. and Akiyoshi, T. The expression of tumor-rejection antigens of MAGE genes. Int. J. Cancer, 62, 523-526 (1995).
12. Kono, K., Rongun, Y., Charo, J., Ichikawa, F., Celis, E., Sette, A., Appella, E., Sekikawa, T., Matsumoto, Y. and Kiessling, R. Identification of HER2/neu-derived peptide epitope recognized by gastric cancer-specific cytotoxic T lymphocytes. Int. J. Cancer, 78, 202-208 (1998).
13. Hoshino, T., Seki, N., Kikuchi, M., Kuramoto, T., Iwamoto, O., Kodama, I., Koufuji, K., Takeda, J. and Itoh, K. HLA class 1-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int. J. Cancer, 70, 631-638 (1997).
14. Yang, D., Nakao, M., Shichijo, S., Sasatomi, T., Takasu, H., Matsumoto, H., Mori, K., Yamana, H., Shirouzu, K. and Itoh, K. A gene coding for a protein possessing shared tumor epitopes capable of inducing cytotoxic T lymphocytes in cancer patients. Cancer Res., 59, 4056-4063 (1999).
15. Imanishi, T., Akazawa, T., Kimura, A., Tokunaga, K. and Gojobori, T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In "HLA 1991," Vol. 1, ed. K. Tsuji, M. Aizawa and T. Sasazuki, pp. 1065-1220 (1992). Oxford Scientific Publ., London.